UNSPSC 51351624: Estradiol hemihydrate

This classification denotes a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CXY7B3Q98Z. European Medicines Agency schedules Estradiol hemihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11941MIG. Estradiol hemihydrate generally arises in the molecular formula 2C18H24O2.H2O. The term 'estradiol hemihydrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule estradiol hemihydrate under HS 29372300.

As of Q4 2014, ESTRADIOL HEMIHYDRATE remains US FDA's Preferred Term for this commodity. Estradiol hemihydrate bears US NLM identifiers UMLS ID C1320235 and NCI Concept Code C47992. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CC[C@@H]2O)O.C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CC[C@@H]2O)O.O.

UNSPSC 51351624 Estradiol hemihydrate is a Commodity code for pharmaceutical active pharmaceutical ingredients and finished dosage forms distributed through state and local government health systems. State and local governments acquire estradiol hemihydrate and related generic multi-source pharmaceuticals primarily through cooperative purchasing vehicles that consolidate demand across multiple jurisdictions and health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active under this code, procuring pharmaceuticals for participating state and local government facilities across multiple states including Oregon. Solicitations under the code emphasize compliance with current Good Manufacturing Practices (cGMP), the Drug Supply Chain Security Act (DSCSA), and FDA requirements, along with product availability through authorized drug wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and capability to support electronic data interchange (EDI) systems for ordering and chargeback management.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, exemplifies recent activity under the code. The solicitation seeks manufacturers to supply finished pharmaceutical products with National Drug Codes (NDCs), detailed SKUs, UPCs, and specified packaging configurations, with pricing weighted heavily on competitiveness (75 percent of evaluation). Proposals must demonstrate pricing flexibility through flat-price, net-price, or WAC-minus structures and maintain minimum insurance coverage including $5 million commercial general liability per occurrence. Contract awards are effective July 1, 2026, with a two-year term for new responders and optional extensions at MMCAP's discretion. Vendors should anticipate a 3 percent administrative fee on all purchases and potential performance penalties of $200 to $1,500 per violation for late reporting or missed onboarding timelines. No specific budget range or award value is disclosed in the solicitation; emphasis falls on product availability, therapeutic considerations, and member-specific needs across the participating cooperative membership.